Genotyping Market by Application Clinical Chemistry and Immunoassay, Vaccination and Industry Forecast, 2030 – ManufactureLink

According to the Market Statsville Group, the global genotyping market size was estimated at $19,952.6 million in 2021 and is expected to grow at a CAGR of 27.3% to reach $137,602.6 million by 2030. Rising prevalence of genetic diseases such as Turner syndrome and Alzheimer’s disease is expected to drive the market. Additionally, growing preference for parents to test and identify genomic abnormalities and various companies offering affordable genetic testing and sequencing services are expected to drive the market.

The introduction of technologically advanced products based on accuracy, efficiency and cost-effectiveness is expected to serve this market as a high-impact rendering engine. Major market players are introducing new technologies which are better, efficient, fast and cost effective to withstand their position in the market. The growing number of automated instruments and their easy availability are factors that are expected to drive the market. Improved technology and subsequent introduction of affordable and high-efficiency products are also driving the market. Most companies provide genotyping services for DNA/RNA sequencing. These services are reliable, personalized and affordable.

Global genotyping market definition

Genotyping is the study of DNA sequences to determine the genetic makeup of living organisms such as humans, plants, animals, and microorganisms. Human genotyping can help determine whether a person is a father or a mother. Genotyping of microorganisms, including viruses and bacteria, helps prevent the spread of pathogens by tracking down the origin of the outbreak.

Get a PDF for more professional and technical information:

Global genotyping market dynamics

Drivers: Increase in the prevalence of genetic diseases

Rising prevalence of genetic diseases, such as Alzheimer’s disease, Turner’s syndrome, and Parkinson’s disease, is one of the major factors that will drive the growth of the market. According to an article published by the National Center for Biotechnology Information in 2017, Parkinson’s disease affects 1 to 2 in 1,000 people and 1% of the population over 60. According to the World Health Organization, cancer was responsible for 8.8 million deaths in 2015. They alter lifestyles and the environmental impact on life triggers the incidence of genetic diseases. The incidence of breast cancer and ovarian cancer is increasing at a higher rate in many regions. Early detection of genetic variations through prenatal testing helps in establishing proper diagnosis, prevention and treatment of the disease. High disease incidence is driving the growth of the genotyping market.

Constraints: Lack of skilled labor

Genotyping on data analysis and management requires high technical know-how. Currently, there are relatively fewer professionals and experts working in this field. Moreover, few institutes and universities offer courses and training in healthcare information technology in developing economies. Therefore, lack of qualified professionals is expected to act as a limiting factor for genotyping and the growth of the associated industry. However, companies are now collaborating with various universities and offering on-site training, online workshops and sponsored projects to develop the right professionals. This should spark the interest of research professionals and fellows by helping them to realize the potential of this field and, therefore, significantly reducing the impact of contention.

You can buy full [email protected]

Scope of the Global Genotyping Market Research Report

The study classifies the genotyping market on the basis of product, technology, and application at regional and global levels.

By Products Insights (RevenueUSD million, 20172030)

  • Reagents and kits
  • Instruments
  • Services

By Technology Insights (Revenue, USD million, 20172030)

  • Polymerase chain reaction (PCR)
  • Capillary electrophoresis
  • Mass spectrometry
  • Sequencing
  • microchip
  • Others

By Outlook app (Sales, million USD, 20172030)

  • Diagnostic
  • Drug discovery and development
  • Personalized medicine
  • University institutes
  • Agriculture
  • Others

Outlook by region (Sales, million USD, 20172030)

  • North America (United States, Canada, Mexico)
  • South America (Brazil, Argentina, Colombia, Peru, Rest of Latin America)
  • Europe (Germany, Italy, France, United Kingdom, Spain, Poland, Russia, Slovenia, Slovakia, Hungary, Czech Republic, Belgium, Netherlands, Norway, Sweden, Denmark, Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Indonesia, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, Philippines, Singapore, Australia and New Zealand, Rest of Asia Pacific)
  • The Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, North Africa, Rest of MEA)

The reagents and kits segment, by product, accounts for the largest market share

On the basis of product, the market is divided into reagents and kits, instruments and services. In 2021, the reagents and kits segment accounted for the largest market share of 55.2% in the global genotyping market. In 2021, Reagents and kits held the largest share and is the fastest growing market due to its high adoption in research and clinical settings. Kits and reagents are available for DNA sequencing, cloning, cell manipulation, PCR, electrophoresis and gene regulation. Standard reagents help achieve efficient and accurate results. Standardized results, improved efficiency, and cost-effectiveness are expected to support the growth of this market. The major market players providing reagents and kits are Affymetrix, Inc.; Thermo Fisher Scientific; Fluidigm Corp; and Agilent Technologies.

Access the full description of the report, Contentsfigure chart, graph, etc. @

Asia Pacific represents the highest CAGR over the forecast period

By regions, the global genotyping market has been segmented into North America, AsiaPacific, Europe, South America, Middle East and Africa. Globally, Asia Pacific is estimated to hold the highest CAGR of 28.2% in the global genotyping market during the forecast period. The Asia-Pacific region includes countries such as China, India, Japan, South Korea, Australia, Southeast Asia and Rest of Asia.Peaceful.

High unmet clinical needs, untapped market opportunities and improving healthcare spending are the major factors responsible for the regional growth. Technological advancements coupled with increasing prevalence of various target diseases are increasing the demand for genotyping products. Moreover, growing demand for healthcare products and initiatives undertaken by governments to improve the health status of the people are expected to drive the market growth over the forecast period.

Request for Report Description @

Main market players

Genotyping market is slightly concentrated in nature with few global players operating in the market such as Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Danaher Corporation, Roche Diagnostics, GE Healthcare, Fluidigm Corporation, PerkinElmer, Eurofins Scientific, Bio-Rad Laboratories, Pacific Biosciences of California, GENEWIZ and Integrated DNA Technologies. Each company follows its own business strategy to achieve the maximum market share.